Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Abecma idecabtagene vicleucel Multiple myeloma Do not reimburse Complete
Abilify Aripiprazole Depression, Major Depressive Disorder Do not list Complete
Abilify Aripiprazole Schizophrenia and related psychotic disorders List with clinical criteria and/or conditions Complete
Abilify Aripiprazole Schizophrenia Do not list Complete
Abilify Maintena Aripiprazole Schizophrenia List with criteria/condition Complete
Abraxane Nab-paclitaxel Metastatic Pancreatic Cancer Reimburse with clinical criteria and/or conditions Complete
Abstral Fentanyl citrate Pain, breakthrough cancer pain Do not list Complete
Aclasta Zoledronic acid Osteoporosis, postmenopausal women Do not list Complete
Aclasta Zoledronic acid Osteoporosis List with clinical criteria and/or conditions Complete
Actemra Tocilizumab Arthritis, polyarticular juvenile idiopathic List with criteria/condition Complete
Actemra Tocilizumab Arthritis, rheumatoid List with criteria/condition Complete
Actemra Tocilizumab Arthritis, Rheumatoid List with clinical criteria and/or conditions Complete
Actemra Tocilizumab Arthritis, juvenile idiopathic List with clinical criteria and/or conditions Complete
Actemra tocilizumab Giant cell arteritis (GCA) Reimburse with clinical criteria and/or conditions Complete
Actikerall Fluorouracil and Salicylic Acid Hyperkeratotic actinic keratosis Reimburse with clinical criteria and/or conditions Complete
Adcetris Brentuximab vedotin Withdrawn
Adcetris Brentuximab Vedotin Primary cutaneous anaplastic large cell Lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) Reimburse with clinical criteria and/or conditions Complete
Adcetris Brentuximab Vedotin Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) Reimburse with clinical criteria and/or conditions Complete
Adcetris Brentuximab Vedotin peripheral T-cell lymphoma (PTCL) Reimburse Complete
Adcetris Brentuximab Vedotin HL at high risk of relapse or progression post-ASCT Reimburse with clinical criteria and/or conditions Complete
Adcetris Brentuximab vedotin Systemic Anaplastic Large Cell Lymphoma Reimburse with clinical criteria and/or conditions Complete
Adcetris Brentuximab vedotin Hodgkin Lymphoma Reimburse with clinical criteria and/or conditions Complete
Adcetris Brentuximab vedotin Hodgkin lymphoma Active
Adcetris brentuximab vedotin Hodgkin lymphoma Withdrawn
Adcetris (Resubmission) Brentuximab Vedotin Hodgkin lymphoma (HL) Do not reimburse Complete